267 related articles for article (PubMed ID: 34605345)
1. Pharmacological strategies for improving the prognosis of glioblastoma.
Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
[No Abstract] [Full Text] [Related]
2. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide for immunomodulation in the treatment of glioblastoma.
Karachi A; Dastmalchi F; Mitchell DA; Rahman M
Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
[TBL] [Abstract][Full Text] [Related]
5. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.
Bhaskaran M; Devegowda VG; Gupta VK; Shivachar A; Bhosale RR; Arunachalam M; Vaishnavi T
ACS Chem Neurosci; 2020 Oct; 11(19):2962-2977. PubMed ID: 32945654
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
11. Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Umlauf BJ; Frampton G; Cooper A; Greene HF
J Control Release; 2023 Dec; 364():195-205. PubMed ID: 37865172
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Yasaswi PS; Shetty K; Yadav KS
J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001
[TBL] [Abstract][Full Text] [Related]
14. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
15. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
16. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Rezaei V; Rabiee A; Khademi F
J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
[TBL] [Abstract][Full Text] [Related]
18. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161
[TBL] [Abstract][Full Text] [Related]
19. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
20. Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Wang J; Zuo J; Wahafu A; Wang MD; Li RC; Xie WF
CNS Neurosci Ther; 2020 Mar; 26(3):297-308. PubMed ID: 31318172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
